Pfizer is an American pharmaceutical company. It is among the world's best 3 drug manufacturers. It was founded in 1849.
The issuer's stock is traded on the Nyse stock exchange. The beta coefficient is 0.585 according to investing.com. The asset can be considered as protective. It loses less value than most other stocks during trade downturns.
The current dividend yield is 5.86%. This equals $1.68 per share. The company has increased its payout for 13 consecutive years. Therefore, it is suitable for a dividend strategy.
On 11/04/2024 PFE prices are likely to rise. Experts point to the positive market sentiment. The company is expected to improve its fundamentals and improve earnings.
Price Today — $28.09 USD.
Price at Q1 of 2024 — $27.75.
Price for next year 2025 — $20.
Long-term price 2025-2030 — $20-$52.
Positive price momentum is expected in the coming month. Technical analysis gives a strong buy signal. According to Tipranks, the overall consensus of Wall Street analysts is Moderate Buy. The average price target for Pfizer over the next 12 months is $31.92.
On the 1MN timeframe, the technical learning indicates a strong sell rating for the asset. But there are also terms that suggest buying. At the time of writing:
assets have appreciated in 6 of the last 10 days;
chart is above the moving averages;
2 bullish candlestick patterns appear on the 1H timeframe.
The value of the asset is close to the upper border of the moderate upward trend. The chart is close to the upper Bollinger Band. Breaking the $29.75 level will be a sign of strengthening bullish sentiment. The following support levels are $28.55 and $27.49. A breach below these levels will be a sell signal.
Among the predictions for the coming 5 years there are bullish and bearish scenarios. Expectations of price decline are based on the weaknesses of the company. They are pointed out by Aditya Shastri in his review. The key issue is the risk of losing market assets. The company has a strict pricing policy. And its research costs are lower than those of its main competitors.
The bulls point to the following positive factors:
long history, brand recognition;
operating in more than 180 countries;
strong workforce, quality employee training program.
Despite this, the company faces serious challenges in 2024. Covid's vaccine and drugs no longer contribute much to the earnings.
A phase III trial of Danugliprone was halted at the end of 2023. This is a weight loss drug that investors had big hopes for. The company's debt became greater in 2023. By March 2024, it was $68.70 billion. The reason is the cost of buying Seagen.
Even in the most optimistic scenario, the asset's value will grow only 1.6x over 5 years. Given these projections, this asset is more suitable for people looking for passive income in the form of dividends. In a bearish scenario, assets could lose over 40% and fall below $20.
Most stock analysts expect the share price to stabilize in 2024. They are confident that the company will post similar revenues in 2023. Meanwhile, net savings will grow to $2 billion.
Some experts believe that PFE shares could rise as early as 2024. This is due to plans to reduce debt and improve operating margins.
Leading analyst target prices:
$29 — Morgan Stanley;
$32 — TD Cowen;
$36 — BMO Capital Markets;
$45 — Cantor Fitzgerald.
Month |
Minimum expected price, $ |
Maximum expected price, $ |
Change, % |
July |
28.076 |
28.661 |
1.94 |
August |
28.004 |
28.631 |
-1.98 |
September |
27.326 |
27.920 |
-2.17 |
October |
27.101 |
27.415 |
0.37 |
November |
27.462 |
28.071 |
2.17 |
December |
28.152 |
28.442 |
0.76 |
Expectations for 2025 are represented by many services. The target prices are lower than the predictions of Wall Street analysts for 2024. It is also unlikely that the issuer's revenues and earnings will reach 2021-2022 levels.
The main growth driver for the financial results will be the contribution from Seagen. In addition, PFE is expected to launch new products.
End 2025 target levels:
$28.43 — LongForecast;
$29.16 — Coincodex;
$33.06 — Stockraven;
$35.01 — CoinPriceForecast.
Month |
Minimum expected price, $ |
Maximum expected price, $ |
Change, % |
January |
26.807 |
28.371 |
-5.77 |
February |
26.035 |
26.705 |
-2.5 |
March |
25.845 |
26.602 |
2.49 |
April |
26.259 |
26.664 |
-1.31 |
May |
26.170 |
26.464 |
0.94 |
June |
25.982 |
26.483 |
-1.7 |
July |
26.031 |
26.627 |
2 |
August |
26.011 |
26.609 |
-2.21 |
September |
25.291 |
25.924 |
-2.5 |
October |
25.077 |
25.410 |
0.51 |
November |
25.435 |
25.995 |
2.15 |
December |
26.080 |
26.407 |
1.05 |
Analysts are divided on the future of Pfizer. Bulls expect the release of new products in demand. This will lead to improved financial performance. Bears believe that the company will not be able to beat 2021-2022 sales in the coming years.
In accord with the Stock Analysis Service, 2026 sales will be in the range of $59.4 billion to $69.2 billion. This is down from the 2022 level of $100.33 billion. Expected EPS is $2.47-$3.71.
Potential end-2026 asset value:
$29.80 — Coincodex;
$33.58 — LongForecast;
$35.44 — Stockraven;
$38.05 — CoinPriceForecast.
Month |
Minimum expected price, $ |
Maximum expected price, $ |
Change, % |
January |
24.831 |
26.340 |
-5.88 |
February |
24.051 |
24.710 |
-2.67 |
March |
23.829 |
24.556 |
2.49 |
April |
24.195 |
24.627 |
-1.64 |
May |
24.143 |
24.415 |
0.72 |
June |
23.961 |
24.460 |
-1.86 |
July |
23.987 |
24.589 |
2.33 |
August |
23.929 |
24.543 |
-2.56 |
September |
23.283 |
23.890 |
-2.61 |
October |
23.035 |
23.357 |
0.61 |
November |
23.386 |
24.005 |
2.58 |
December |
24.030 |
24.378 |
1.06 |
According to the stock testing, EPS will be between $2.43 and $3.73 in 2027. Even in the maximum scenario, this result is lower than in 2021-2022. But exceeds the 2023 level.
Many experts are optimistic. They believe that prices in 2027 will be more expensive than the current price. Their reasoning is on the basis of investors' desire for riskier assets. Against the background of lower interest rates, the asset market will receive an inflow of liquidity.
Target prices for 2027:
$20.84 — LongForecast;
$30.45 — Coincodex;
$39.75 — CoinPriceForecast;
$40.28 — Stockraven;
$43.08 — Stockscan.
Month |
Minimum expected price, $ |
Maximum expected price, $ |
Change, % |
January |
22.861 |
24.329 |
-6.39 |
February |
22.069 |
22.720 |
-2.88 |
March |
21.780 |
22.536 |
2.59 |
April |
22.176 |
22.583 |
-1.32 |
May |
22.106 |
22.386 |
0.95 |
June |
21.943 |
22.431 |
-1.92 |
July |
21.936 |
22.561 |
2.77 |
August |
21.896 |
22.522 |
-2.86 |
September |
21.216 |
21.882 |
-3.14 |
October |
20.998 |
21.302 |
0.27 |
November |
21.335 |
21.955 |
2.83 |
December |
21.999 |
22.348 |
1.37 |
The bears expect the capitalization to be lower in 5 years than it is now. They point out that the company spends less on research than its peers. This means that new drugs may be delayed.
Bulls claim the company has one of the top distribution networks among pharmaceutical companies worldwide. This is a major benefit. The most positive projection for 2028 promises a 60% growth in prices compared to early June 2024 levels.
Expected end-2028 asset price:
$17.51 — LongForecast;
$30.53 — Stockscan;
$31.11 — Coincodex;
$40.94 — Stockraven;
$46.67 — CoinPriceForecast.
Month |
Minimum expected price, $ |
Maximum expected price, $ |
Change, % |
January |
20.737 |
22.247 |
-7.28 |
February |
19.921 |
20.688 |
-3.85 |
March |
19.737 |
20.533 |
3.06 |
April |
20.159 |
20.556 |
-1.7 |
May |
20.072 |
20.370 |
1.07 |
June |
19.891 |
20.397 |
-1.91 |
July |
19.989 |
20.534 |
2.49 |
August |
19.817 |
20.491 |
-3.36 |
September |
19.217 |
19.843 |
-3.1 |
October |
18.966 |
19.290 |
0.73 |
November |
19.295 |
19.931 |
3.02 |
December |
20.014 |
20.317 |
1.38 |
Experts are divided on the outlook for Pfizer. Advocates of the bullish scenario believe that increased demand for pharmaceutical products is positive for all companies in the industry. They expect the market for pharmaceuticals to expand compared to the past. The main reason for this is the increase in the average age of the population.
Key Opportunities for PFE Development:
expansion of non-US presence;
new mergers and acquisitions in the pipeline;
launch of new cancer drugs.
The current financial problems are pointed out by the bears. Their expectation is that the company will not be able to solve these problems and that there will be a further decline in the company's share price.
Most of the options for how this is going to play out seem bullish. Experts are of the opinion that after 10 years the capitalization of the company will be 2 times bigger than the current one. But there are also pessimistic scenarios. They assume a decrease in the value of the company by up to 2.5 times.
2034 PFE Price Assumptions:
$11.62 — Stockscan
$61.56 — Stockraven;
$62.48 — CoinPriceForecast.
BeatMarket analysts are bullish. We believe that the company will be able to maintain its leadership position. And the growing healthcare segment and new progresses in Oncology will allow earnings to continue to grow.
The Motley Fool's experts point to a problem facing Pfizer by decade's end. It is set to lose several key patents. There is no information about the existence of events that would be a guarantee of compensation. As a result, bears are on the lookout for a decline in earnings and capitalization.
The bulls call the issuer undervalued. The company's focus on oncology is a point of emphasis for bulls. By 2030, PFE's top management plans to produce 8 or more effective cancer drugs.
2030 Share Value Expectations:
$2.43 — Stockscan;
$32.49 — Coincodex;
$47.94 — Stockraven;
$52.16 — CoinPriceForecast.
Long-term stock forecasts are based on mathematical calculations. They take into account data from previous years. Quotes modeling services offer 2 scenarios of events:
$9.02 — Stockscan;
$81.05 — Stockraven;
BeatMarket analysts are positive on the pharmaceutical company. We see no reason to expect the company to lose significant market assets.
Some analysts see PFE trading below $5 by 2050. Others predict a 3.5x or more multiple:
$4.41 — Stockscan;
$110.85 — Stockraven.
We believe that a bearish scenario is unlikely to occur. The healthcare segment is poised for extraordinary growth. PFE is a brand with a long history and an experienced team. It is very likely that it will continue to bring in-demand events to the market.
It is the second largest pharmaceutical company worldwide. It was valued at $166.08 billion as of June 2024. The manufacturer specializes in 4 categories: vaccines, hospitals, internal medicine, inflammation and immunology.
One of the key contents is oncology research. Among the best-known drugs are Advil, Viagra, Xanax and Zoloft. In 2023, the European Commission approved Abrysvo, a RSV vaccine.
The company ships products to more than 180 countries. However, its leading market is still the USA. Its main competitors are GSK plc, Merck & Co. and Vivus.
1994-1999
A long bullish trend was observed in quotations. Over 5 years, the share price increased more than 8 times. The click was mainly with the launch of new drugs.
2021
In December, the company's capitalization reached an all-time high. This was due to positive news about a vaccine against Covid-19.
2024
At the beginning of 2024, the quotations reached the local bottom. The 12- month price has fallen by almost a quarter. The main reason is losses due to a decline in demand for coronavirus drugs. Investments led to an increase in debt against the backdrop of high borrowing costs.
Success in innovation, the launch of a new drug, is positive for a pharmaceutical company's stock. Unfavorable test results lead to falling prices.
A major negative detail is reported adverse reactions to marketed drugs. This reduces confidence in the brand and demand for products. It can also be the cause of fines and a deterioration in financial performance.
The drug giant's stock price is subject to economic factors. These are Fed rates, GDP dynamics, etc. The company's own results are also important - sales, net earnings, profitability, key multiples, etc.
Over the next 12 months, most analysts expect the stock to appreciate. The top target price is $45.
In accord with Investing.com, as of the beginning of June, it has an average analyst rating of “hold”. It was given by 16 respondents. Another 9 advised investors to buy the stock. No expert gave a sell rating.
Different analysts provide very different projections. The average price target for the stock represents a range of $26 to $35.
It depends on the investor's objectives and investment horizon. People who are interested in big dividends should pay attention to this company.
Pfizer had its maximum price on December 16, 2021. Its asset price reached $61.25 on that day.
התאמן בקהילה של אנשים בעלי דעות דומות, ותוכל לצעוד צעד אחר צעד לרמה חדשה בהשקעה!
הצטרף לקהילה שלנובוצע